BiomX is no longer a clinical-stage phage company. After the inhaled cystic-fibrosis program was stopped and the Israeli operating subsidiary entered insolvency, a new chief executive used the listed shell to buy two small Israeli security firms with stock, notes, and warrants. The debate is whether those purchases start a real counter-drone and infrastructure platform, or whether they merely rebrand a cash-empty residual claim. Mid-year cash was only $347 thousand. That balance is the entire operating cushion against a first-half cash burn that already consumed several times that amount.
The June quarter booked the first product revenue in company history, all of it from the April purchases of ZorroNet and a controlling stake in Dr. Frucht Systems. First-half sales were $332 thousand. First-half net loss reached $23 million, swollen by warrant remeasurement and a day-one financing charge rather than by operating scale. Goodwill and other intangibles from those deals now make up almost the entire asset base. The equity story therefore lives or dies on whether Israeli pilots convert into funded multi-year contracts before the at-the-market program and the related-party credit line are exhausted.
Management states that existing funds plus hoped-for subsidiary receipts cover only the next several months, and the June quarterly filing itself raises substantial doubt about continuation as a going concern. After the quarter closed the company executed a one-for-ten reverse split, changed its name to Tessera Defense and Homeland Security, and began trading under a new symbol. The open question is whether a recapitalization and a real defense contract arrive before cash, listing status, or both give out.